| Literature DB >> 33814750 |
Neha Chauhan1, R Shankar Prasad2.
Abstract
Chemical burns account for a small percentage of burns but contribute to significant number of burn-related mortalities. The major challenge posed by chemical burns is difficulty in correct depth estimation, as the damage continues to progress until they are effectively neutralized. Besides the most common etiology of chemical burns by alkalis and acids, there are many other unique causes of chemical burns. The author describes a case of chemical burns by heavy duty paint remover, the main composition of which is methylene chloride. Although several studies about methylene chloride poisoning are available in literature, only one case report of burns due to methylene chloride exists in literature. These burns are unique in their presentation. The author describes the presentation and challenges in management of this burn. Clinical trial registration Not applicable. Association of Plastic Surgeons of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Keywords: chemical burns; dichloromethane burns; methylene chloride burns
Year: 2021 PMID: 33814750 PMCID: PMC8012789 DOI: 10.1055/s-0041-1725224
Source DB: PubMed Journal: Indian J Plast Surg ISSN: 0970-0358
| Drug | Dose and frequency | Route of administration |
|---|---|---|
| Abbreviations: CPAP, continuous positive airway pressure; DVT, deep vein thrombosis; IPPV, intermittent positive pressure ventilation; SIMV, synchronized intermittent mandatory ventilation. | ||
| Injection amiodarone | 300 mg | Intravenous infusion |
| Injection cefoperazone/sulbactum | 3 g stat followed by 1.5 g twice a day for 5 days | Intravenous |
| Injection clindamycin | 600 mg thrice a day for 5 days | Intravenous |
| Normal saline | 100 mL/hour for 2 days then tapered and stopped | Intravenous |
| Levosalbutamol sulfate 1.25 mg + ipratropium bromide 150 µcg in 2.5 mL | 2.5 ml respule four times a day for 1 week | Nebulization |
| Budesonide 0.5 mg | 2 mL respule four times a day for 1 week | Nebulization |
| Injection midazolam | Started at 1 mg/hour; titrated over 48 hours as per patient’s behavioral pain scale score and then stopped | Intravenous |
| Injection fentanyl | Started at 100micrograms/hour; titrated over 48 hours as per patient’s behavioral pain scale score and then stopped | Intravenous |
| Injection noradrenalin | Started at 40 nanograms/kg body weight/min; titrated as per patient’s mean arterial blood pressure and stopped after 48 hours. | Intravenous |
| Ventilation | Patient put on IPPV mode; then, shifted to SIMV mode, CPAP mode, and finally put on T-piece. Initially, FiO2 was kept at 70% and then reduced to 50% after 4 hours as he started maintaining SPO2 of 100% with lesser oxygen requirement. Thereafter, it was further weaned off. | |
| Supportive measures | Ryle’s tube in situ for 72 hours after which it was removed. | |
Fig. 1Burns right side of face. Patient on ventilatory support after cardiopulmonary resuscitation (day 1 of admission).
Fig. 2Burns front of Face. (2 months later).